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Verapamil and other slow channel calcium antagonists 
have been reported to retard atherosclerosis in rabbits 
fed a high cholesterol diet. Because atherosclerosis in 
such a model may differ significantly from human ath-
erosclerosis, experiments were conducted to prevent ath-
erosclerosis with verapamil in the Watanabe heritable 
hyperlipidemic (WHHL) rabbit, which is a genetic, met-
abolic and pathologic model of homozygous familial hy-
percholesterolemia. At 2 months of age, 23 WHHL rab-
bits were divided into two groups since earlier studies 
showed no macroscopic a~herosclerosis at 2 months. Group 
A (n = 11) was fed standard rabbit chow for 6 months. 
Group B (n = 12) received oral verapamil (46 mg/kg 
per day) absorbed in the identical chow as fed to Group 
Calcium, both within and outside arterial walls, may pro-
mote atherogenesis by several mechanisms (1-6). A variety 
of agents that interfere with the deposition of Ca + + in the 
arterial wall have been shown to retard experimentally in-
duced atherosclerosis (6-13). Recent studies (6,12,13) have 
focused on the efficacy of slow channel Ca + + antagonists 
in decreasing the incidence of atherosclerosis in New Zea-
land white rabbits fed a high cholesterol diet. However, 
atherogenesis in this setting differs importantly from human 
atherogenesis (14). 
Recently, an animal model of familial hypercholestero-
lemia has been described (15-17). The Watanabe heritable 
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A and subcutaneous verapamil (0.25 mg/kg twice daily 
6 days a week). In Group B, mean serum verapamil 
concentrations (± SEM) averaged 16.9 ± 1.9 ng/ml at 
3 hours after subcutaneous injection. Sex ratios and serum 
cholesterol concentrations were the same;n botl} groups. 
The percent of aortic surface area with visible plaque in 
Group A versus B was 49 ± 7 versus 43 ± 7%, re-
spectively, of the entire aorta, and 61 ± 5 versus 65 ± 
5 %, respectively, of the proximal 3 cm of aorta (p = 
NS). Thus, verapamil did not suppress atherQsclerosis 
in WHHL rabbits at serum drug levels greater than those 
reported to be effective in other models. 
(J Am Coli CardioI1985;6:141-4) 
hyperlipidemic (WHHL) rabbit exhibits spontaneous hy-
percholesterolemia due to elevated levels of low density 
lipoprotein, accelerated atherosclerosis including raised aor-
tic plaques at 6 to 8 months of age and tendinous xanthomas 
(16). The gross distribution and light and electron micro-
scopic features of developing atherosclerosis in WHHL rab-
bits resemble those of homozygous familial hypercholes-
terolemia and perhaps other forms of human atherosclerosis 
( 16, 17). The purpose of the present study was to assess the 
efficacy of a slow channel Ca + + antagonist, verapamil, in 
reducing spontaneous aortic atherosclerosis in the WHHL 
rabbit. 
Methods 
Treatment groups. Since previous work from this in-
stitution (16) has shown that there is no gross aortic ath-
erosclerosis in WHHL rabbits at 2 months of age, 23 rabbits, 
2 months old, were allocated by sex to two treatment groups 
for 6 months. Group A (II control rabbits) was fed standard 
rabbit chow (Zeigler Brothers, Inc.). Group B (12 rabbits) 
was given oral and parenteral verapamil. For oral intake, 
0735-10971851$3.30 
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verapamil powder (Knoll Pharmaceuticals) was absorbed in 
standard rabbit chow (Zeigler Brothers, Inc.) as described 
previously (13). The concentration of vempamil ranged from 
50 to 100 mgt 1 00 g chow. As the weight of the rabbits rose, 
increasingly concentrated verapamil chow was provided to 
achieve at least 30 mg/kg per day of oral verapamil intake. 
In addition, 0.25 mg/kg of verapamil was injected subcu-
taneously at 8:00 AM and 5:00 PM for 6 of 7 days weekly. 
In vivo measurements. Weight, hematocrit, total serum 
cholesterol, serum verapamil levels and quantity of oral 
verapamil intake were measured at regular intervals. Body 
weights were measured at the beginning of the study and 
biweekly thereafter. Every 2 weeks, body weights were used 
to calculate daily oral intake of verapamil and adjust par-
enteral and oral doses of verapamil for Group B. Hematocrit 
and total serum cholesterol levels were measured at control 
and at 3 and 6 months. Serum cholesterol was assayed by 
established techniques (I8). Serum verapamil levels were 
measured in Group B 60 to 90 minutes after subcutaneous 
injections at 3 and 6 months and 3 hours after injection at 
6 months. The samples for serum verapamil determinations 
were drawn with heparinized syringes, transferred to hep-
arinized glass containers, immersed immediately in ice and 
promptly centrifuged. The serum was transferred to plastic 
vials, frozen and shipped to Bio-Science, Chicago, Illinois, 
where samples were analyzed for verapamil concentration 
by high pressure liquid chromatography (19). 
Postmortem studies. After 6 months of placebo or ve-
rapamil treatment, the rabbits received an intravenous in-
jection of 1,000 U of heparin and a lethal dose of pento-
barbital. The heart and the aorta, as far distally as possible, 
were removed with instruments cleansed in nitric acid to 
avoid contaminating the tissue with Ca + +. The adventitia 
was removed thoroughly and the aorta immersed in phys-
iologic saline solution to wash away adherent blood. The 
extent of aortic atherosclerosis and the concentration of aor-
tic and cardiac tissue calcium were determined as follows. 
The aortic lumen was opened longitudinally and pinned 
endothelial side up to a cork board. Full length and close-
up portions of the aorta were photographed on Kodachrome 
film. The entire aortic surface area and the percent exhibiting 
atherosclerotic plaques were estimated by planimetry from 
8 x 10 inch (20.3 x 25.4 cm) color prints with computer 
assistance. The same measurements were performed on the 
first 3 cm of the ascending aorta, which was the most in-
volved aortic segment. A small strip (approximately 3 x 
10 mm) was removed from the proximal (first 3 cm) and 
distal aorta, fixed in formalin and processed for histologic 
examination. Tissue calcium concentration was measured 
in the basal two-thirds of the heart and in the proximal and 
distal aorta. The tissues were placed in preweighed vials 
that had been previously cleansed with nitric acid and washed 
in double distilled water with a resistance of 18 n. After 
the wet weight of tissues was recorded, specimens were 
dried overnight at 105°C to obtain dry weights, dissolved 
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in 2 ml of concentrated nitric acid followed by 1 ml of 
perchloric acid, concentrated to 1 ml by boiling and diluted 
in 1 % lanthanum solution (20). Measurements were made 
with a Perkin-Elmer model 303 atomic absorption spectro-
photometer and expressed as ng/mg dry weight. The mea-
surements of aortic atherosclerosis and tissue Ca + + were 
made without knowledge of the experimental groups. 
Statistical analysis. Comparisons between treatment 
groups were performed by the two-tailed Student's group t 
test and Welch's approximation of the t test when unequal 
variances indicated the use of a nonparametric procedure. 
Values are expressed as mean ± standard error of mean. 
Results 
Table 1 summarizes the results. There were no significant 
differences between treatment groups in sex ratio, duration 
of therapy, weight, hematocrit or serum cholesterol levels. 
The total area of aorta dissected for analysis was 12.1 ± 
0.4 cm2 in Group A compared with 13.6 ± 0.6 cm2 in 
Group B (p = NS). The percent of proximal and total aorta 
with atherosclerotic plaques was the same in both groups. 
In Group A versus B, the percent plaque in the proximal 
aorta was 61 ± 5 versus 65 ± 5%, respectively, and in 
the entire aorta 49 ± 7 versus 43 ± 7%, respectively. 
Figure 1 shows photographs representative of aortic athero-
Table 1. Results in Control (Group A) and Treated 
(Group B) Rabbits 
Group A Group B 
Male/female ratio 5/6 517 
Treatment duration (mo) 6.3 ± 0.2 6.3 ± 0.1 
Weight (kg) 
Start 1.42 ± 0.08 1.53 ± 0.04 
End 3.66 ± 0.15 3.77 ± 0.08 
Hematocrit 
Start 40 ± 0.6 41 ± 0.5 
End 44 ± 0.9 44 ± 0.1 
Serum cholesterol (mg/dl) 
Start 617 ± 32 685 ± 53 
End 552 ± 43 556 ± 38 
Total aortic surface area (cm2) 12.1 ± 0.4 13.6 ± 0.6 
Percent aortic plaque 
Proximal 3 cm 61 ± 5 65 ± 5 
Total aorta 49 ± 7 43 ± 7 
Tissue Ca + + content (ng/mg dry weight) 
Proximal aorta* 656 ± 275 2547 ± 704* 
Distal aorta * 317 ± 63 536 ± 63* 
Heart 68 ± 6 54 ± 4* 
Daily oral verapamil intake (mg/kg) None 46 ± 2 
Serum verapamil concentration (ng/ml) 
I h after injectiont Undetectable 52.1 ± 3.8 
3 h after injection Undetectable 16.9 ± 1.9 
*In normal New Zealand white rabbits (n == 3), the Ca+ + content 
measured 37 ± 4 ng/ml dry weight in the proximal aorta and 45 ± 2 
ng/ml dry weight in the distal aorta. t Average of measurements at 3 lind 
6 months. *p < 0.05. Data are reported as mean values ± SEM. 
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Figure 1. Typical aortic specimens showing the extent of athero-
sclerosis. The top two aortas are from control Group A. The 
bottom two aortas are from verapamil-treated Group B. In these 
photographs, the normal aortic tissue is dark and the atherosclerotic 
plaques are pale. Each photograph inCludes a metric ruler (smallest 
division = I mm). 
sclerosis in both treatment groups. Histologic examination 
revealed atheromatous plaques in both groups with features 
similar to those described previously (16). In Group B, the 
proximal and distal aortic samples had significantly higher 
and the hearts significantly lower concentrations of tissue 
calcium. 
Discussion 
Calcium and atherosclerosis. Despite evidence that 
Ca + + may promote atherosclerosis (1-6) and that slow 
channel calcium antagonists retllrd atherosclerosis experi-
mentally induced by feeding a high cholesterol diet (6-13), 
this study indicates that verapamil has no effect on the 
development of spontaneous atherosclerosis in the Watanabe 
heritable hyperlipidemic (WHHL) r.abbit. By inference, 
therefore, verapamil may also have no effect on human 
atherosclerosis as is seen in familial hypercholesterolemia. 
Atherogenesis is a complex process involving alterations 
in endothelial permeability, phagocytosis of lipoproteins and 
smooth muscle cell proliferation in arterial intima with se-
cretion of collagen, elastin and glycosaminoglycans (l). 
Hypercholesterolemia has been reported (6) to elevate serum-
ionized Ca + +, and Ca + + may promote atherogenesis by 
at least several mechanisms: 1) stimulating the synthesis of 
high energy phosphates for atherosclerotic processes, 2) 
increasing endothelial permeability by causing vascular 
smooth muscle contraction, 3) binding low density lipopro-
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tein and other lipoproteins to glycosaminoglycans in arterial 
walls, 4) inducing the migration of ceUs into developing 
atheromata, and 5) increasing the production of elastin and 
other molecules prominent in atherosclerotic plaques (2-6). 
Observations such as these have led to interest in the use 
of slow channel calcium antagonists for suppressing the 
development of atherosclerosis. 
The rabbit model. Several investigators (6,12,13) have 
reported a reduction in atherosclerosis after treating New 
Zealand rabbits, maintained on high cholesterol feedings, 
with slow channel calcium antagonists. Atherosclerosis in 
this model has several important features not seen in human 
beings: 1) lesions are, for the most part, confined to the 
stage of fatty streaks and foam cells, which are of monocyte 
or macrophage origin with a minor smooth muscle cell com-
ponent, 2) these foam cell lesions are associated with very 
high circulating levels of a lipoprotein called /3-VLDL rather 
than low density lipoprotein (LDL), 3) lipid deposition oc-
curs in the reticuloendothelial system, and 4) small vessel 
involvement is prominent (14). Therefore, the relevance of 
the findings in these studies to human atherogenesis is 
uncertain. 
In contrast, the WHHL rabbit is an animal model of one 
form of human atherosclerosis, homozygous familial hy-
percholesterolemia. Features common to both include: de-
ficient cell surface receptors for low density lipoprotein, 
spontaneously elevated serum cholesterol levels (90% low 
density lipoprotein), accelerated atherosclerosis, cutaneous 
xanthomatosis and a lack of lipid accumulation in the re-
ticuloendothelial system (16). Unlike atherosclerotic lesions 
in cholesterol-fed rabbits, lesions in WHHL rabbits contain 
lipid-laden smooth muscle cells as a prominent component 
of the foam cells and have well developed plaques (16). 
Verapamil and atherosclerosis. The failure of vera-
pamil to reduce atherosclerosis in this animal model is prob-
ably due to the fact that atherosclerosis in WHHL rabbits 
is pathophysiologically different from that in cholesterol-
fed rabbits as outlined. This was supported by the fact that 
our protocol had fivefold higher oral doses, similar paren-
teral doses and 50% higher serum concentrations of vera-
pamil than previously reported as effective in retarding ath-
erogenesis (13). In addition, the significantly lower cardiac 
calcium concentration in Group B is additional evidence 
that our method of administering verapamil had physiologic 
effects. However, we cannot exclude the possibility that 
differences in methodology contributed to the negative re-
sults in our study. First, drug therapy and cholesterol feed-
ings were begun simultaneously in other studies (6,12,13), 
while we began verapamil 2 months after birth. Hypercho-
lesterolemia had been present since birth and possibly in 
utero. However, at 2 months of age, WHHL rabbits have 
no gross atherosclerosis and only occasional microscopic 
fatty streaks (16). Second, two previous studies (12,13) 
quantified the extent of atherosclerosis after staining the 
aortas with lipophilic dyes, while this study quantified the 
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extent of disease on the basis of macroscopically visible 
lesions identified without the aid of lipophilic dyes. Third, 
the duration of previous studies (6,12,13) was 8 to IO weeks 
versus 6 months in this investigation. Nonetheless, the dif-
ferences in methodology appear inadequate to explain the 
total failure of verapamil to reduce atherosclerosis in Group 
B. Finally, it is unlikely that the small number of rabbits 
in each group caused our study to miss a significant reduc-
tion of atherosclerosis in Group B, since the percent of aortic 
atherosclerosis was almost identical in Groups A and B. 
The higher aortic calcium concentrations in Group B 
(verapamil group) were unexpected. There are at least two 
possible explanations. Group B could have developed more 
complex or advanced atherosclerotic plaques with larger 
tissue calcium concentrations due to secondary calcification. 
However, there were no obvious histologic differences in 
the lesions among the two groups. Second, the higher aortic 
calcium concentrations in Group B may have been due to 
a rebound phenomenon. The nocturnal feeding habits of 
rabbits and the limitation of twice daily injections in our 
protocol would be expected to cause daily episodes of un-
detectable plasma verapamil levels, which might lead to 
excessive tissue calcification during such nadirs. The modest 
serum verapamil concentrations at 3 hours after subcuta-
neous injections support that hypothesis. Other investigators 
(6,12) reported decreased aortic calcium concentrations in 
cholesterol-fed rabbits treated with calcium antagonists. 
However, in those studies, serum drug levels were not re-
ported and the atherosclerosis was confined to fatty streaks, 
which may lead to less intense tissue calcification than do 
the thick, complex atheromas in WHHL rabbits. Therefore, 
even though our serum verapamil levels were 50% higher 
than those previously reported to be successful in suppress-
ing experimental aortic atherosclerosis (13), the elevated 
aortic calcium concentrations in Group B raise the possi-
bility that even higher or more frequent doses are necessary 
to suppress atherogenesis in the WHHL rabbit. However, 
our parenteral dose of verapamil was the highest dose pos-
sible without leading to congestive heart failure or death as 
previously reported (13). 
Conclusion. Although verapamil and other slow chan-
nel calcium antagonists have been shown to reduce diet-
induced atherosclerosis in the rabbit model, verapamil had 
no such effect on the development of spontaneous athero-
sclerosis in the WHHL rabbit, an animal model of the human 
disease, familial hypercholesterolemia. 
We acknowledge the technical assistance of Glenda Bird and Dr. Suresh 
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